Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition containing NAD (Nicotinamide Adenine Dinucleotide) and CD38 inhibitor and application thereof

A CD38 and composition technology, applied in the field of NAD-containing pharmaceutical compositions, can solve the problems of weakening the effect of NAD, limiting wide clinical applications, low NAD supplementation efficiency, etc., and achieving the effect of enhancing the effect and expanding the therapeutic range.

Active Publication Date: 2022-04-12
HEFEI KNATURE BIO PHARM CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The efficiency of NAD supplementation is too low, which greatly weakens the role of NAD in the prevention and treatment of diseases and limits its wide clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing NAD (Nicotinamide Adenine Dinucleotide) and CD38 inhibitor and application thereof
  • Pharmaceutical composition containing NAD (Nicotinamide Adenine Dinucleotide) and CD38 inhibitor and application thereof
  • Pharmaceutical composition containing NAD (Nicotinamide Adenine Dinucleotide) and CD38 inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Adriamycin cardiotoxicity model construction method

[0032] Eight-week-old C57BL / 6 male mice were injected with 5 mg / kg of doxorubicin or normal saline into the tail vein, once a week for four consecutive weeks. Four weeks after the last administration, the mice were subjected to echocardiography to detect the heart function of the mice, and the myocardial tissue of the mice was taken to detect the NAD content.

Embodiment 2

[0034] Blank control group: the mice were intraperitoneally injected with the same volume of normal saline as that of the experimental group, the administration frequency was once a day, and the duration period was the same as that of the DIC model administration period. After the administration, echocardiography was performed on the mice to detect the heart function of the mice, and the myocardial tissue of the mice was taken to detect NAD + content.

[0035] NAD synthase Nampt agonist group: NAD synthase Nampt agonist P7C3 was dissolved in DMSO, and mice were injected intraperitoneally with 20 mg / kg NAD synthase Nampt agonist P7C3. same. After the administration, the myocardial tissue of the mice was taken to detect NAD + content.

[0036] NAD-depleting enzyme PARP inhibitor group: NAD-depleting enzyme PARP inhibitor Olaparib was dissolved in DMSO, and mice were injected intraperitoneally with 10 mg / kg NAD-consuming enzyme PARP inhibitor Olaparib. The frequency of Olapari...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of pharmaceutical compositions, and particularly relates to a pharmaceutical composition containing NAD (Nicotinamide Adenine Dinucleotide) and application thereof. The invention provides a pharmaceutical composition containing NAD (Nicotinamide Adenine Dinucleotide). The pharmaceutical composition comprises NAD and a CD38 inhibitor. The pharmaceutical composition enhances the prevention and / or treatment effect of NAD on cardiotoxicity caused by cancer chemotherapy drugs, and expands the treatment range of NAD.

Description

technical field [0001] The invention belongs to the field of pharmaceutical compositions, and in particular relates to NAD-containing pharmaceutical compositions and applications thereof. Background technique [0002] Anthracyclines, represented by doxorubicin, are an important class of chemotherapy drugs, which are widely used in the treatment of solid and hematological malignancies, such as breast cancer, acute leukemia, and lymphoma. However, doxorubicin-induced cardiotoxicity (DIC) severely limits its clinical application. Although the new liposomal doxorubicin has improved the targeting of tumors, its cardiotoxicity has not been completely eliminated. Once congestive heart failure caused by doxorubicin occurs, the fatality rate is as high as 50%. At present, there is no effective treatment for DIC. Dextropropanimine is the only drug approved by the FDA for the prevention of DIC. However, its poor effect and side effects force people to constantly look for new and effe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7084A61P9/00A61P39/02A61K31/4709
CPCA61K31/7084A61P9/00A61P39/02A61K31/4709
Inventor 葛均波孙爱军罗伟王伟王康林王磊张倍健董正翁鑫宇赵永超
Owner HEFEI KNATURE BIO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com